Research programme: RNA therapeutics- Arcturus Therapeutics/ Synthetic Genomics

Drug Profile

Research programme: RNA therapeutics- Arcturus Therapeutics/ Synthetic Genomics

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arcturus Therapeutics; Synthetic Genomics
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 31 Oct 2017 Arcturus Therapeutics and Synthetic Genomics agree to co-develop RNA therapeutics worldwide
  • 31 Oct 2017 Arcturus Therapeutics has patent protection for LUNAR lipid-mediated delivery and UNA technology including UNA oligomers in USA, Europe, Japan, China and other countries
  • 31 Oct 2017 Arcturus Therapeutics has patents pending for LUNAR lipid-mediated delivery and UNA technology including UNA oligomers in USA, Europe, Japan, China and other countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top